Neuralstem, Inc.  

(Public, NYSEMKT:CUR)   Watch this stock  
Find more results for NYSEAMEX:CUR
3.36
0.00 (0.00%)
Jan 26 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range     -
52 week 2.12 - 4.81
Open     -
Vol / Avg. 1,850.00/1.07M
Mkt cap 293.53M
P/E     -
Div/yield     -
EPS -0.24
Shares 87.36M
Beta 1.47
Inst. own 20%
Mar 9, 2015
Q4 2014 Neuralstem Inc Earnings Release (Estimated) Add to calendar
Feb 9, 2015
Neuralstem Inc at Biotechnology Industry Organization CEO & Investor Conference - 3:30PM EST - Add to calendar
Jan 13, 2015
Neuralstem Inc at EBD Biotech Showcase
Nov 7, 2014
Q3 2014 Neuralstem Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -89104.80% -18028.96%
Operating margin -82135.00% -11384.64%
EBITD margin - -11162.67%
Return on average assets -57.58% -140.83%
Return on average equity -79.54% -257.71%
Employees 15 -
CDP Score - -

Address

9700 Great Seneca Highway
ROCKVILLE, MD 20850
United States - Map
+1-301-3664841 (Phone)
+1-302-7301370 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Neuralstem, Inc. (Neuralstem) is engaged in development and commercialization of treatments based on our human neuronal stem cells and our small molecule compounds. Neuralstem's technology enables the production of neural stem cells of the brain and spinal cord in commercial quantities and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glial cells. Neuralstem also maintains the ability to generate stable human neural stem cell lines suitable for systematic screening of large chemical libraries. The Company is developing products using technology, including Cell Therapy and Small Molecule Pharmaceutical Compounds. The Company�s products include NSI-566 and NSI � 189.

Officers and directors

Karl Johe Ph.D. Chairman of the Board, Chief Scientific Officer
Age: 53
Bio & Compensation  - Reuters
I. Richard Garr J.D. President, Chief Executive Officer, Chief Financial Officer, General Counsel, Director
Age: 61
Bio & Compensation  - Reuters
Sandford Drexel Smith Director
Age: 67
Bio & Compensation  - Reuters
Scott V. Ogilvie Independent Director
Age: 58
Bio & Compensation  - Reuters
William C. Oldaker Independent Director
Age: 72
Bio & Compensation  - Reuters
Catherine Angell Sohn Independent Director
Age: 61
Bio & Compensation  - Reuters
Stanley I. Westreich Independent Director
Age: 75
Bio & Compensation  - Reuters